Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenetic Biosciences, Inc.XBIO · Entity 8008 | Director · CEO | December 20, 2016 | June 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenetic Biosciences, Inc.
Report date December 20, 2016 · Filed June 15, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2026-12-20 | Direct | 83,333 |
Reported balance
After 2016-12-20 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2016-12-20 · Grant · Acquired 83,334 · Balance 83,333 F1: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. F2: On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that he beneficially owned an aggregate of 433,786 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2026-12-20 | Direct | 166,667 |
Reported balance
After 2016-12-20 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2016-12-20 · Grant · Acquired 83,333 · Balance 166,667 F1: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. F2: On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that he beneficially owned an aggregate of 433,786 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2026-12-20 | Direct | 250,000 |
Reported balance
After 2016-12-20 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2016-12-20 · Grant · Acquired 83,333 · Balance 250,000 F1: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. F2: On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that he beneficially owned an aggregate of 433,786 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date.
F2: On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that he beneficially owned an aggregate of 433,786 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2016 Filed Dec 23, 2016 14:20 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 83,333 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662252-16-000305 · form4.xml · derivative · entry 3 Maguire Michael Scott · CIK 0001690490 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,786 Underlying: Common Stock · 83,333 shares Expires 2026-12-20 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. Read SEC document |
| December 20, 2016 Filed Dec 23, 2016 14:20 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 83,333 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662252-16-000305 · form4.xml · derivative · entry 2 Maguire Michael Scott · CIK 0001690490 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,453 Underlying: Common Stock · 83,333 shares Expires 2026-12-20 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. Read SEC document |
| December 20, 2016 Filed Dec 23, 2016 14:20 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 83,334 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662252-16-000305 · form4.xml · derivative · entry 1 Maguire Michael Scott · CIK 0001690490 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,120 Underlying: Common Stock · 83,334 shares Expires 2026-12-20 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. Read SEC document |
| December 20, 2016 Filed Jun 15, 2017 17:14 UTC Amendment | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 83,333 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662252-17-000123 · form4a.xml · derivative · entry 3 Maguire Michael Scott · CIK 0001690490 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 83,333 shares Expires 2026-12-20 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. F2 · balance_after: On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that he beneficially owned an aggregate of 433,786 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction. Read SEC document |
| December 20, 2016 Filed Jun 15, 2017 17:14 UTC Amendment | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 83,333 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662252-17-000123 · form4a.xml · derivative · entry 2 Maguire Michael Scott · CIK 0001690490 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 Underlying: Common Stock · 83,333 shares Expires 2026-12-20 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. F2 · balance_after: On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that he beneficially owned an aggregate of 433,786 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction. Read SEC document |
| December 20, 2016 Filed Jun 15, 2017 17:14 UTC Amendment | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 83,334 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662252-17-000123 · form4a.xml · derivative · entry 1 Maguire Michael Scott · CIK 0001690490 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,334 shares Expires 2026-12-20 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date. F2 · balance_after: On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that he beneficially owned an aggregate of 433,786 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.